로딩 중…
지수 로딩 중…
L&K Biomed Ltd.
156100· KOSDAQ· Health Care· Health Care Equipment & Services
₩5,910+0.34%
2026-09-18
Financials
Valuation Metrics
L&K Biomed Ltd.'s Market Cap is ₩1321B. At end of 2025 it was ₩2897B. Ranked #1097 of 2,421 in KR market (top 45%), #570 of 1,640 on KOSDAQ (top 35%), #39 of 96 in Health Care Equipment & Services (top 41%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 132.10B KRW | KR#1,097/2,421 Sec#39/96 |
| Revenue | 39.94B KRW | KR#1,913/2,421 Sec#56/96 |
| Net Income | 2.13B KRW | KR#1,403/2,421 Sec#43/96 |
| Total Assets | 109.67B KRW | KR#1,701/2,421 Sec#52/96 |
| Net Assets | 56.54B KRW | KR#1,823/2,421 Sec#57/96 |
| Employees | 81 | KR#1,803/2,421 Sec#70/96 |
| Value | ||
| P/E | 62.15x | KR#1,442/2,421 Sec#46/96 |
| P/B | 2.34x | KR#2,012/2,421 Sec#72/96 |
| PEG | 10.71x | KR#822/2,421 Sec#32/96 |
| P/S | 3.31x | KR#2,020/2,421 Sec#66/96 |
| EV/EBITDA | 297.25x | KR#1,543/2,421 Sec#49/96 |
| FCF Yield | -12.77% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | 3.76% | KR#1,255/2,421 Sec#41/96 |
| ROA | 1.94% | KR#1,231/2,421 Sec#45/96 |
| Op. Margin | 1.30% | KR#1,474/2,421 Sec#50/96 |
| Revenue Growth | -0.11% | KR#1,537/2,421 Sec#75/96 |
| Earnings Growth | 5.81% | KR#777/2,421 Sec#32/96 |
| Financial Health | ||
| Debt Ratio | 93.95% | KR#1,498/2,421 Sec#75/96 |
| Total Debt | 26.97B KRW | KR#1,276/2,421 Sec#33/96 |
| FCF | -16.87B KRW | KR#1,855/2,421 Sec#73/96 |
| Cash | 4.64B KRW | KR#2,028/2,421 Sec#72/96 |
| Current Ratio | 1.89x | KR#922/2,421 Sec#54/96 |
| Net Debt/EBITDA | 42.97x | KR#1,473/2,421 Sec#47/96 |
| Performance | ||
| 1Y Return | -32.92% | KR#1,646/2,421 Sec#47/96 |
| 1M Return | 47.75% | KR#57/2,421 Sec#3/96 |
| From 52W High | -63.96% | KR#2,000/2,421 Sec#69/96 |
| 1Y MDD | -82.41% | KR#2,334/2,421 Sec#91/96 |
| Trading | ||
| Volume | 293,169 shares | KR#363/2,421 Sec#12/96 |
| Trading Value | 1.76B KRW | KR#585/2,421 Sec#13/96 |
| Foreign Own. | 7.16% | KR#624/2,421 Sec#18/96 |
| Per Share | ||
| EPS | 95 KRW | KR#1,430/2,421 Sec#43/96 |
| BPS | 2,530 KRW | KR#1,948/2,421 Sec#62/96 |
Company Info
동사는 2008년 척추 임플란트 개발, 제조, 판매를 시작으로 현재 6개의 비상장 종속회사를 보유하고 있음. 정형외과와 신경외과의 척추고정장치 및 척추 수술용 제품 설계, 개발, 제조, 판매를 주요 사업으로 하고 있으며, 경추용과 흉요추용 제품 라인업을 갖추고 있음. 척추 전문 임플란트 기술 및 연구개발 노하우를 바탕으로 Pectus Bar System 개발을 완료하고 FDA 허가를 받아 흉부임플란트 분야로 확장하고 있음. 엘앤케이바이오는 2008년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.